ABL DiagnosticsXPAR:ABLD +0.76%51 Interest Coverage is 8.09 as of Dec. 2025, which is 100% below its 10-year median of 10,000.00. GuruFocus rates XPAR:ABLD with a GF Score™ of 51/100 and a GF Value™ of €7.71 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 453 Healthcare Providers & Services companies, ABL Diagnostics ranks worse than 67.33% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. ABL Diagnostics's
Operating Income
for the
six
months ended in Dec. 2025 was €0.36 Mil. ABL Diagnostics's Interest Expense for the
six
months ended in Dec. 2025 was €-0.04 Mil.
ABL Diagnostics's interest coverage for the quarter that ended in Dec. 2025 was 8.09.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for ABL Diagnostics's Interest Coverage or its related term are showing as below:
XPAR:ABLD'
s Interest Coverage Range Over the Past 10 Years
Min: 3.92 Med: No Debt Max: No Debt
Current: 3.92
XPAR:ABLD's Interest Coverage is ranked worse than 67.33% of 453
companies
in the Healthcare Providers & Services industry
Industry Median: 8
vs XPAR:ABLD: 3.92
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
ABL Diagnostics Interest Coverage Related Terms
ABL Diagnostics Interest Coverage Historical Data
* Premium members only.
The historical data trend for ABL Diagnostics's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
XPAR:ABLD vs VEEV, BTSG, TEM: Interest Coverage Comparison
For the Health Information Services subindustry, ABL Diagnostics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ABL Diagnostics Interest Coverage vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, ABL Diagnostics's Interest Coverage distribution charts can be found below:
* The bar in red indicates where ABL Diagnostics's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABL Diagnostics (XPAR:ABLD) has a Interest Coverage of 8.09 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on ABL Diagnostics and its competitors. This is 100% below median its historical median of 10,000.00. Over the past decade, ABL Diagnostics' Interest Coverage has ranged from 3.92 to 10,000.00. According to the industry distribution chart, ABL Diagnostics ranks #305 out of 453 companies in the Healthcare Providers & Services industry, placing it in the top 67.3%.
Is ABL Diagnostics' Interest Coverage too high?
ABL Diagnostics' current Interest Coverage of 8.09 is 100% below median its 10-year median of 10,000.00. Over the past 10 years, this metric has ranged from a low of 3.92 to a high of 10,000.00. The Healthcare Providers & Services industry median Interest Coverage is 8.00. ABL Diagnostics' value of 8.09 is 1.1% above this industry median. Based on the distribution chart, ABL Diagnostics ranks #305 out of 453 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, ABL Diagnostics has a GF Score™ of 51/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ABL Diagnostics' Interest Coverage compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, ABL Diagnostics ranks #305 out of 453 companies for Interest Coverage. This places ABL Diagnostics in the lower half of its industry. The industry median Interest Coverage is 8.00. ABL Diagnostics' value of 8.09 is 1.1% above this benchmark. Historically, ABL Diagnostics' own Interest Coverage has ranged from 3.92 to 10,000.00 over the past decade. While the company's 10-year median is 10,000.00 vs. the industry median of 8.00, ABL Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Healthcare Providers & Services company?
The median Interest Coverage among Healthcare Providers & Services companies is 8.00, based on 453 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ABL Diagnostics's current Interest Coverage of 8.09 is 1.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on ABL Diagnostics and its competitors. For the Healthcare Providers & Services industry, the median Interest Coverage is 8.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ABL Diagnostics's current Interest Coverage is 8.09, which is 100% below median its own 10-year median of 10,000.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABL Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, ABL Diagnostics (XPAR:ABLD) is currently considered Significantly Undervalued. The stock's GF Value™ is €7.71, compared to a current price of €2.66 — trading 65.5% below its estimated fair value. The current Interest Coverage is 8.09, which is 100% below median its 10-year median of 10,000.00 and 1.1% above the Healthcare Providers & Services industry median of 8.00. ABL Diagnostics' overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For ABL Diagnostics (XPAR:ABLD), the current Interest Coverage is 8.09 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ABL Diagnostics (XPAR:ABLD) Overvalued in 2026?
Based on GuruFocus' analysis, ABL Diagnostics stock appears to be undervalued.
The current stock price of €2.66 is trading 65.5% below its estimated GF Value™ of €7.71.
GuruFocus considers ABL Diagnostics to be Significantly Undervalued.
Key valuation signals for XPAR:ABLD:
Interest Coverage: 8.09 (100% below median its 10-year median of 10,000.00)
GF Value™: €7.71 vs. price of €2.66 (65.5% below fair value)
Industry Position: 1.1% above the Healthcare Providers & Services median (#305 of 453)
No single metric tells the full story. See the XPAR:ABLD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.
51GF Score
Get the complete analysis for XPAR:ABLD
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ABLD has been successfully added to your 
